profit from every €100 of sales.
€0€100
Evotec
€3.14-0.70% today
-39.7% since Dec 16, 25
1-year low €2.441-year high €6.55
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Evotec sold, what it kept, and what it did with the cash.
Sales went from €751 million in 2022 to €788 million in 2025, with -€104 million of profit last year.
SalesProfit
Evotec vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Evotec | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.6× · Expensive |
AI analysis
An AI analyst reads Evotec's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 751 | 781 | 797 | 788 | |
| 174 | 175 | 115 | 114 | |
| 21 | -27 | -79 | -56 | |
| -58 | 24 | -81 | 27 | |
| -176 | -84 | -196 | -104 | |
| -0.99 | -0.47 | -1.11 | – | |
| 23.2% | 22.4% | 14.4% | 14.5% | |
| 2.8% | -3.4% | -9.9% | -7.1% | |
| -23.4% | -10.7% | -24.6% | -13.1% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,257 | 2,252 | 1,913 | 1,714 |
| Cash | 401 | 511 | 293 | 402 |
| Total debt | 507 | 626 | 444 | 448 |
| Total liabilities | 1,070 | 1,133 | 960 | 900 |
| 1,187 | 1,120 | 953 | 814 | |
| 177 | 177 | 177 | – | |
| -5.8% | -2.8% | -9.1% | -4.0% | |
| -14.8% | -7.5% | -20.6% | -12.7% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 206 | 36 | 18 | -9 | |
| 181 | 216 | 132 | 83 | |
| 24 | -180 | -114 | -92 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| – | 0 | 0 | 2 | |
| 10 | 10 | 5 | 4 |
Valuation
- –
- –
- –
- 1.2×
- 0.7×
- –
- 22.3×
- -16.4%
- -18.5%
- 0.0%
Profitability
- 14.5%
- -7.1%
- -13.1%
- –
- -4.0%
- -5.4%
- –
- –
- –
- –
Growth
- +1.6%
- –
- –
- –
- +2.1%
Financial health
- 1.7×
- 0.55
- –
- -5.0×
- 2.07
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 32%of 948
Bottom 17%of 871
Bottom 18%of 868
Bottom 6%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
54No pass
Philip Fisher
25No pass
Peter Lynch
26No pass
Joel Greenblatt
0No pass
Charlie Munger
24No pass
Terry Smith
25No pass
Questions about Evotec
Is Evotec a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Evotec AI analysis
What does Evotec do?
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. It is in Drug Manufacturers - Specialty & Generic.
Does Evotec pay a dividend?
No. Evotec does not pay a dividend at the moment; in 2025 it returned €1.55 million to shareholders by buying back its own shares.
Is Evotec stock halal?
No. Evotec does not pass our halal screen: its debt is 80% of its market value, at or above the 33% limit. How we check
Who are Evotec's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Evotec's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.